Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt ~~or solvate~~ thereof



(I)

wherein

R^1 and R^2 independently represent H or C1 to 6 alkyl, said alkyl being optionally further substituted by an acyl ring or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said aromatic ring being optionally further substituted by halogen, CF_3, C1 to 4 alkyl or C1 to 4 alkoxy;

```
=> fil cap
FILE 'CAPLUS' ENTERED AT 11:05:54 ON 12 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 12 Jan 2009 VOL 150 ISS 3
FILE LAST UPDATED: 11 Jan 2009 (20090111/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d que l12
L9 STR



VAR G1=H/15/16
REP G2=(1-3) 18
VAR G3=S/19
NODE ATTRIBUTES:
NSPEC IS RC AT 11
NSPEC IS RC AT 18
CONNECT IS E1 RC AT 15
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 15
GGCAT IS SAT AT 16
GGCAT IS UNS AT 17
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L11 35 SEA FILE=REGISTRY SSS FUL L9
L12 10 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L11

=> d l12 ibib abs hitstr tot

L12 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:874350 CAPLUS Full-text
DOCUMENT NUMBER: 147:257652
TITLE: Preparation of piperidine derivatives as tachykinin receptor antagonists
INVENTOR(S): Shirai, Junya; Yoshikawa, Takeshi; Sugiyama, Hideyuki
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 133pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007089031	A1	20070809	WO 2007-JP52160	20070201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-763894P P 20060201
OTHER SOURCE(S): MARPAT 147:257652
GI



I



II

AB Title compds. I [Ar = (un)substituted phenyl; R1 = H, (un)substituted hydrocarbyl, acyl or heterocyclyl; Z = (un)substituted methylene; ring A = (un)substituted piperidine; B = (un)substituted monocyclic aromatic heterocyclyl with provisions that substituents may form a ring], and their pharmaceutically acceptable salts, prodrugs are prepared and disclosed as tachykinin receptor antagonists and useful as an agent for the prophylaxis or treatment of lower urinary tract disease and the like. Thus, e.g., II was prepared by condensation of N-[2-((3R,4S)-4-amino-3-phenylpiperidin-1- yl)-2-oxoethyl]acetamide methanesulfonate (preparation given) with 4-(5-formyl-6-methoxypyridin-3-yl)benzonitrile (preparation given) followed by reduction I have superior antagonistic activity, e.g., II showed IC50 value of 0.015 nM.

IT 945954-65-4P 945954-79-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperidine derivs. as tachykinin receptor antagonists)

RN 945954-65-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[2-[(3R,4S)-4-[[[2-cyclopropyl-4-methoxy-6-(1-methylethoxy)-5-pyrimidinyl]methyl]amino]-3-phenyl-1-piperidinyl]-2-oxoethyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 945954-79-0 CAPLUS
CN Benzonitrile, 4-[5-[[[(3R,4S)-1-[2-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)acetyl]-3-phenyl-4-piperidinyl]amino]methyl]-6-methoxy-3-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:705062 CAPLUS Full-text
DOCUMENT NUMBER: 147:118148
TITLE: Piperidine derivatives as tachykinin receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of lower urinary tract symptoms, gastrointestinal and central nerve disease
INVENTOR(S): Ikeura, Yoshinori; Shirai, Junya; Yoshikawa, Takeshi; Sakauchi, Nobuki
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 89pp., Cont.-in-part of Appl. No. PCT/JP2006/315899.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070149570	A1	20070628	US 2007-701380	20070202
WO 2007015588	A1	20070208	WO 2006-JP315899	20060804

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-227183 A 20050804
WO 2006-JP315899 A2 20060804

OTHER SOURCE(S): MARPAT 147:118148
GI



I



II

AB The invention relates to a compound represented by formula I or a salt thereof. Compds. of formula I wherein Ar is (un)substituted Ph; R1 is H, (un)substituted hydrocarbon, acyl and (un)substituted heterocyclic group; R2 is H, (un)substituted C1-6 alkyl and (un)substituted C3-6 cycloalkyl; Z is (un)substituted methylene; ring A is a (un)substituted piperidine ring; ring B and ring C are (un)substituted benzene; R2 optionally form a ring together with the adjacent substituent on the ring B; and their salts thereof, are claimed. The compound of the invention has a superior tachykinin receptor antagonistic action, particularly a substance P receptor antagonistic action, and is useful as a pharmaceutical agent, for example, tachykinin receptor antagonist, an agent for the prophylaxis or treatment of lower urinary tract symptoms, gastrointestinal diseases or central nerve diseases. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their tachykinin receptor antagonistic activity. From the assay, it was determined that compound II exhibited an IC50 value of 0.019 nM.

IT 923280-44-8P 923280-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperidine derivs. as tachykinin receptor antagonists and their use in the treatment of lower urinary tract symptoms, gastrointestinal and central nerve disease)

RN 923280-44-8 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3'-[[[(3R,4S)-1-[2-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)acetyl]-3-phenyl-4-piperidinyl]amino]methyl]-4'-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 923280-84-6 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 3'-[[[(3R,4S)-1-[[1-[2-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)acetyl]-4-piperidinyl]carbonyl]-3-phenyl-4-piperidinyl]amino]methyl]-4'-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:485967 CAPLUS Full-text
DOCUMENT NUMBER: 146:482087
TITLE: Preparation of heterocyclic amide compounds as matrix metalloproteinase inhibitors
INVENTOR(S): Nara, Hiroshi; Kaieda, Akira; Sato, Kenjiro; Terauchi, Jun
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 330pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007049820	A1	20070503	WO 2006-JP322043	20061027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006306991	A1	20070503	AU 2006-306991	20061027
CA 2627497	A1	20070503	CA 2006-2627497	20061027
EP 1953148	A1	20080806	EP 2006-822961	20061027

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

MX 200805416 A 20080512 MX 2008-5416 20080425
KR 2008066061 A 20080715 KR 2008-712886 20080528
PRIORITY APPLN. INFO.: JP 2005-315267 A 20051028
WO 2006-JP22043 W 20061027
WO 2006-JP322043 W 20061027

OTHER SOURCE(S): MARPAT 146:482087
GI



I

AB The title compds. I [A = zinc-bonding group; X = CZ, N; Z = H, halo; Y = (un)substituted spacer having 2 to 10 atoms; ring B = Q1, etc.; R1 - R4 = H, halo, cyano, etc.; excluding 6 specific compds.] are prepared Thus, 4-oxo-N-[3-([2-((1H-1,2,4-triazol-3-ylthio)ethyl]oxy)phenyl)methyl]-3,4-dihydroquinazoline-2-carboxamide was prepared in several steps starting from 3-hydroxybenzonitrile and 1-bromo-2-chloroethane. In an in vitro assay, compds. of this invention at 1 μM gave 81% to 100% inhibition of matrix metalloproteinase 13. Formulations are given.

IT 935759-87-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic amide compds. as matrix metalloproteinase inhibitors)

RN 935759-87-8 CAPLUS

CN 2-Quinazolinecarboxamide, N-[[3-[4-[2-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)acetyl]-1-piperazinyl]phenyl]methyl]-3,4-dihydro-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:150254 CAPLUS Full-text
DOCUMENT NUMBER: 146:206214
TITLE: Preparation of biphenylmethylaminopiperidines as

tachykinin receptor antagonists.
INVENTOR(S): Ikeura, Yoshinori; Shirai, Junya; Yoshikawa, Takeshi; Sakauchi, Nobuki
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 174pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007015588	A1	20070208	WO 2006-JP315899	20060804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1910292	A1	20080416	EP 2006-782685	20060804
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20070149570	A1	20070628	US 2007-701380	20070202
PRIORITY APPLN. INFO.:			JP 2005-227183 A	20050804
			WO 2006-JP315899 W	20060804

OTHER SOURCE(S): MARPAT 146:206214
GI



I

AB Title compds. [I; Ar = (substituted) Ph; R1 = H, (substituted) hydrocarbyl, acyl, heterocyclyl; R2 = H, (substituted) alkyl, cycloalkyl; Z = (alkyl-substituted) methylene; all rings may be further substituted; with 2 specifically excluded compds.], were prepared Thus, N-[2-[(3R,4S)-4-[[(4'-ethynyl-4-methoxybiphenyl-3-yl)methyl]amino]-3- phenylpiperidin-1-yl]-2-oxoethyl]acetamide (general preparation given) showed radioligand receptor binding inhibitory activity in IM-9 human lymphoblast cells with IC50 = 0.015 nM.

IT 923280-84-8P 923280-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenylmethylaminopiperidines as tachykinin receptor antagonists)

RN 923280-44-8 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3'-[[[(3R,4S)-1-[2-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)acetyl]-3-phenyl-4-piperidinyl]amino]methyl]-4'-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 923280-84-6 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3'-[[[(3R,4S)-1-[[1-[2-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)acetyl]-4-piperidinyl]carbonyl]-3-phenyl-4-piperidinyl]amino]methyl]-4'-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1155411 CAPLUS Full-text

DOCUMENT NUMBER: 145:471540

TITLE: Preparation of piperidine derivatives as tachykinin receptor antagonists

INVENTOR(S): Nagaoka, Naomi; Marunaka, Shigeyuki; Fukuta, Makoto

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 323pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006115285	A1	20061102	WO 2006-JP308919	20060421

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-124335 A 20050421

OTHER SOURCE(S): MARPAT 145:471540

AB The title compds. (no biol. data) are prepared This document discloses a pharmaceutical composition comprising N-(2-[(3R,4S)-4-((2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl)amino)-3-phenylpiperidin-1-yl]-2-oxoethyl)acetamide (I), a salt or a prodrug thereof, a sugar and a hydrophilic water-insol. substance. Thus, N-(2-[(3R,4S)-4-((2-hydroxy-5-[5-(trifluoromethyl)-1H-tetrazol-1- yl]benzyl)amino)-3-phenylpiperidin-1-yl]-2-oxoethyl)acetamide was prepared in 3 steps from (3R,4S)-4-amino-3-phenylpiperidine-1-carboxylic acid tert-Bu ester and 2-hydroxy-5-[5-(trifluoromethyl)-1H-tetrazol-1- yl]benzaldehyde. Formulations containing I are given. Tablets containing I showed high elution stability.

IT 632352-46-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. as tachykinin receptor antagonists)

RN 632352-46-6 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[2-[(3R,4S)-4-[[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]amino]-3-phenyl-1-piperidinyl]-2-oxoethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:272922 CAPLUS Full-text

DOCUMENT NUMBER: 144:331270

TITLE: Preparation of piperidine derivatives as tachykinin receptor antagonists

INVENTOR(S): Ikeura, Yoshinori; Hashimoto, Tadatoshi; Nishida, Haruyuki; Shirai, Junya; Sakauchi, Nobuki

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006030975	A1	20060323	WO 2005-JP17538	20050916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1790636	A1	20070530	EP 2005-785870	20050916
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20060142337	A1	20060629	US 2006-358070	20060222
PRIORITY APPLN. INFO.:			JP 2004-272639 A	20040917
			WO 2005-JP17538 W	20050916

OTHER SOURCE(S): MARPAT 144:331270

GI



I



II

AB Title compds. I [Ar = (un)substituted aryl; R = alkyl; R1 = H, (un)substituted hydrocarbon, acyl, etc.; X = O, (un)substituted imino; ring A = piperidine ring which may have an addnl. substituent; ring B = substituted benzene] were prepared For example, compound II [Y = H]·HCl was prepared from (3R,4S)-4-hydroxy-3-phenylpiperidine-1- carboxylic acid tert-Bu ester in a multistep process. In radioligand receptor binding inhibition assays, compound II [Y = (1-acetylpiperidin-4-yl)carbonyl] exhibited the IC50 value of 0.026 nM. Compds. I are claimed useful for the treatment of irritable bowel disease, depression, etc.

IT 880092-22-8P 880092-48-8P 880092-89-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine derivs. as tachykinin receptor antagonists for treatment of irritable bowel disease, depression, etc.)

RN 880092-22-8 CAPLUS
CN 1H-1,2,4-Triazole-3-acetamide, N-[trans-4-[[(3R,4S)-4-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-1-piperidinyl]carbonyl]cyclohexyl]-2,5-dihydro-5-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 880092-48-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[2-[(3R,4S)-4-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-1-piperidinyl]-2-oxoethyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 880092-89-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[2-[4-[[(3R,4S)-4-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-1-piperidinyl]carbonyl]-1-

piperidinyl]-2-oxoethyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1106854 CAPLUS Full-text
DOCUMENT NUMBER: 143:387043
TITLE: Preparation of triazolone derivatives as MMP inhibitors for the treatment of asthma
INVENTOR(S): Eriksson, Anders; Lepistoe, Matti
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095362	A1	20051013	WO 2005-SE448	20050329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1732903	A1	20061220	EP 2005-722275	20050329
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1960979	A	20070509	CN 2005-80017672	20050329
JP 2007530672	T	20071101	JP 2007-506108	20050329
US 20070219217	A1	20070920	US 2006-593543	20060920
IN 2006DN05541	A	20070803	IN 2006-DN5541	20060922
PRIORITY APPLN. INFO.:			SE 2004-850 A	20040330
			WO 2005-SE448 W	20050329

OTHER SOURCE(S): CASREACT 143:387043; MARPAT 143:387043
GI



I



II

AB Title compds. represented by the formula I [wherein R1, R2 = independently H, Cl or (un)substituted alkyl; R3, R4 = independently H, Cl, (un)substituted alkyl or R3R4 = (hetero)cyclyl; m = 1-3; X = SO, SO2 or CO; R5 = H, Cl or (un)substituted alkyl; Y = a direct bond or NR5Y = azacyclic ring; L = a direct bond, O, amino, etc.; Gl = (un)substituted cyclic ring; and pharmaceutically acceptable salts or solvates thereof] were prepared as metalloproteinase (MMP) inhibitors. For example, II was provided in a multi-step synthesis starting from the reaction of 5-(chloromethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one with benzyl mercaptan. I were tested for inhibition of human MMP12, MMP9, MMP2, MMP19, MMP14 and MMP8. I and their pharmaceutical compns. are useful as MMP inhibitors for the treatment of asthma or other MMP-12 and/or MMP-9 mediated diseases (no data).

IT 866602-62-2P, N,N-Diethyl-1-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methanesulfonamide
RL: BYP (Byproduct); PREP (Preparation)
(preparation of triazolone derivs. as MMP inhibitors for treatment of asthma)

RN 866602-62-2 CAPLUS

CN 1H-1,2,4-Triazole-3-methanesulfonamide, N,N-diethyl-2,5-dihydro-5-oxo- (CA INDEX NAME)



IT 866602-59-7P, 5-[[[4-[(5-Chloropyridin-2-yl)oxy]piperidin-1-yl]sulfonyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-63-3P, 5-[2-[[4-[(5-Chloropyridin-2-yl)oxy]piperidin-1-yl]sulfonyl]ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-67-7P, 5-[3-[[4-[(5-Chloropyridin-2-yl)oxy]piperidin-1-yl]sulfonyl]propyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-71-3P, 5-[[[4-(4-Chlorophenyl)piperazin-1-yl]sulfonyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-72-4P, 5-[[[4-[(2-Methoxypyrimidin-5-yl)ethynyl]-3,6-dihydropyridin-1(2H)-yl]sulfonyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-73-5P, 5-[[[4-[[2-(Trifluoromethyl)pyrimidin-5-yl]ethynyl]-3,6-dihydropyridin-1(2H)-yl]sulfonyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-74-6P, 5-[[[4-[(2-Cyclopropylpyrimidin-5-yl)ethynyl]-3,6-dihydropyridin-1(2H)-yl]sulfonyl]methyl]-2,4-dihydro-3H-

1,2,4-triazol-3-one 866602-75-7P,
5-[[[4-(4-Chlorophenyl)piperidin-1-yl]sulfonyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-76-8P,
N-Benzyl-1-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methanesulfonamide 866602-77-9P, 1-(5-Oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-N-(2-phenylethyl)methanesulfonamide 866602-78-0P,
5-[2-[[4-(4-Chlorophenyl)piperidin-1-yl]sulfonyl]ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-79-1P,
5-[2-[[4-(4-Chlorophenyl)piperazin-1-yl]sulfonyl]ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-80-4P,
5-[3-[[4-(4-Chlorophenyl)piperidin-1-yl]sulfonyl]propyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 866602-81-5P,
5-[3-[[4-(4-Chlorophenyl)piperazin-1-yl]sulfonyl]propyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolone derivs. as MMP inhibitors for treatment of asthma)

RN 866602-59-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[4-[(5-chloro-2-pyridinyl)oxy]-1-piperidinyl]sulfonyl]methyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-63-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[2-[[4-[(5-chloro-2-pyridinyl)oxy]-1-piperidinyl]sulfonyl]ethyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-67-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[3-[[4-[(5-chloro-2-pyridinyl)oxy]-1-piperidinyl]sulfonyl]propyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-71-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]methyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-72-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[3,6-dihydro-4-[2-(2-methoxy-5-pyrimidinyl)ethynyl]-1(2H)-pyridinyl]sulfonyl]methyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-73-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[3,6-dihydro-4-[2-[2-(trifluoromethyl)-5-pyrimidinyl]ethynyl]-1(2H)-pyridinyl]sulfonyl]methyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-74-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[4-[2-(2-cyclopropyl-5-pyrimidinyl)ethynyl]-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]methyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-75-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]methyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-76-8 CAPLUS
CN 1H-1,2,4-Triazole-3-methanesulfonamide, 2,5-dihydro-5-oxo-N-(phenylmethyl)- (CA INDEX NAME)



RN 866602-77-9 CAPLUS
CN 1H-1,2,4-Triazole-3-methanesulfonamide, 2,5-dihydro-5-oxo-N-(2-phenylethyl)- (CA INDEX NAME)



RN 866602-78-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[2-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]ethyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-79-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[2-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]ethyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-80-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[3-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]propyl]-1,2-dihydro- (CA INDEX NAME)



RN 866602-81-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[3-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]propyl]-1,2-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:972057 CAPLUS Full-text
DOCUMENT NUMBER: 140:27765
TITLE: Preparation of piperidine derivatives as tachykinin receptor antagonists for treatment of frequent urination and urinary incontinence
INVENTOR(S): Ikeura, Yoshinori; Hashimoto, Tadatoshi; Tarui, Naoki; Shirai, Junya; Yamashita, Masayuki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 264 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003101964	A1	20031211	WO 2003-JP6754	20030529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487688	A1	20031211	CA 2003-2487688	20030529
AU 2003241903	A1	20031219	AU 2003-241903	20030529
BR 2003011425	A	20050315	BR 2003-11425	20030529
EP 1553084	A1	20050713	EP 2003-733151	20030529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671662	A	20050921	CN 2003-818354	20030529
NZ 537330	A	20070427	NZ 2003-537330	20030529
JP 2004285038	A	20041014	JP 2003-154345	20030530
MX 2004PA11730	A	20050714	MX 2004-PA11730	20041125
US 20060167052	A1	20060727	US 2004-516252	20041129
ZA 2004010085	A	20060726	ZA 2004-10085	20041214
IN 2004KN01942	A	20061201	IN 2004-KN1942	20041216
NO 2004005701	A	20050216	NO 2004-5701	20041229
PRIORITY APPLN. INFO.:			JP 2002-159338 A	20020531
			JP 2003-17885 A	20030127
			WO 2003-JP6754 W	20030529

OTHER SOURCE(S): MARPAT 140:27765

GI



AB The title compds. I [wherein Ar = (un)substituted aryl, aralkyl, or heteroaryl; R1 = H, acyl, (un)substituted hydrocarbyl, or heterocyclyl; X = O or (un)substituted NH; Z = (un)substituted CH2; ring A = (un)substituted piperidine; ring B = (un)substituted aryl; with exclusions] or prodrugs or salts thereof are prepared I have excellent tachykinin receptor antagonistic activity, and are useful for the treatment of frequent urination and urinary incontinence (no data). For example, the compound II•xHCl was prepared in a multi-step synthesis. II showed antagonistic activity with IC50 of 0.025 nM against human substance P receptor. Formulations containing I as an active ingredient were also described.

IT 632352-46-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperidine derivs. as tachykinin receptor

antagonists for treatment of frequent urination and urinary incontinence)

RN 632352-46-6 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[2-[(3R,4S)-4-[[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]amino]-3-phenyl-1-piperidinyl]-2-oxoethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:492870 CAPLUS Full-text

DOCUMENT NUMBER: 109:92870

ORIGINAL REFERENCE NO.: 109:15497a,15500a

TITLE: Synthesis of azoles and fused azoles from α-arylhydrazononitriles

AUTHOR(S): Ibrahim, Mohamed Kamal Ahmed; El-Moghayar, Mohamed Riffat Hamza

CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1987), 26B(9), 832-5
CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 109:92870

GI



AB Cyanoacetamides R1C6H4NHN:C(CONH2)CN (R1 = H, Me, Cl) were heated with N2H4 to give pyrazoles I. Also prepared, from cyanoacetamides and HSCH2CO2H, were thiazolinones II (R2 = Cl, CO2H).

IT 115938-45-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 115998-45-3 CAPLUS
CN 1H-1,2,4-Triazole-3-acetamide, 2,5-dihydro-5-oxo-α-(2-phenylhydrazinylidene)- (CA INDEX NAME)



L12 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1977:468245 CAPLUS Full-text
DOCUMENT NUMBER: 87:68245
ORIGINAL REFERENCE NO.: 87:10865a,10868a
TITLE: Structural elucidation of the reaction products from benzonitrile oxide and 1,4-disubstituted urazoles
AUTHOR(S): Hoyer, Georg A.; Boroschewski, Gerhard
CORPORATE SOURCE: Forschungslab., Schering A.-G., Berlin, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1977), 310(3), 255-9
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I II

AB The reaction of benzonitrile oxide with urazoles (I; R = R1 = Me; R = Ph, R1 = Me; R = Me, R1 = Ph; R = R1 = Ph) does not yield the corresponding 1,4-disubstituted 3-(phenylcarbamoyloxy)-Δ2-1,2,4-triazolin-5-ones as previously reported (Sunderdiek, R. et al, 1974), but leads to oxadiazolinones (II; R, R1 as above).
IT 63425-53-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxadiazolinones vs., as reaction products of benzonitrile oxide and urazoles)
RN 63425-53-6 CAPLUS
CN 1H-1,2,4-Triazole-3-acetamide, 4,5-dihydro-1,4-dimethyl-α,5-dioxo-N-phenyl- (CA INDEX NAME)



```
=> fil cap dissabs confsci wpix
FILE 'CAPLUS' ENTERED AT 11:06:19 ON 12 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DISSABS' ENTERED AT 11:06:19 ON 12 JAN 2009
COPYRIGHT (C) 2009 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'CONFSCI' ENTERED AT 11:06:19 ON 12 JAN 2009
COPYRIGHT (C) 2009 Cambridge Scientific Abstracts (CSA)

FILE 'WPIX' ENTERED AT 11:06:19 ON 12 JAN 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

=> d que l23
L19          496 SEA ERIKSSON A/AU OR ERIKSSON ANDER?/AU
L20           38 SEA LEPISTO M/AU OR LEPISTO M ?/AU OR LEPISTO MATT?/AU
L21          613 SEA L19 OR ERIKSSON A ?/AU
L22          643 SEA (L20 OR L21)
L23            7 SEA L22 AND TRIAZOL?


=> dup rem l23
PROCESSING COMPLETED FOR L23
L24            5 DUP REM L23 (2 DUPLICATES REMOVED)
                 ANSWERS '1-4' FROM FILE CAPLUS
                 ANSWER '5' FROM FILE WPIX

=> d l24 ibib abs tot

L24  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2009 ACS on STN  DUPLICATE 1
ACCESSION NUMBER:         2005:1106854  CAPLUS  Full-text
DOCUMENT NUMBER:          143:387043
TITLE:                    Preparation of triazolone derivatives as MMP
                          inhibitors for the treatment of asthma
INVENTOR(S):              Eriksson, Anders; Lepistoe, Matti
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.
SOURCE:                   PCT Int. Appl., 53 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------          ----   --------    -------------------    --------
     WO 2005095362        A1    20051013    WO 2005-SE448          20050329
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

EP 1732903 A1 20061220 EP 2005-722275 20050329
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 1960979 A 20070509 CN 2005-80017672 20050329
JP 2007530672 T 20071101 JP 2007-506108 20050329
US 20070219217 A1 20070920 US 2006-593543 20060920
IN 2006DN05541 A 20070803 IN 2006-DN5541 20060922
PRIORITY APPLN. INFO.: SE 2004-850 A 20040330
WO 2005-SE448 W 20050329
OTHER SOURCE(S): CASREACT 143:387043; MARPAT 143:387043
GI



I



II

AB Title compds. represented by the formula I [wherein R1, R2 = independently H, Cl or (un)substituted alkyl; R3, R4 = independently H, Cl, (un)substituted alkyl or R3R4 = (hetero)cyclyl; m = 1-3; X = SO, SO2 or CO; R5 = H, Cl or (un)substituted alkyl; Y = a direct bond or NR5Y = azacyclic ring; L = a direct bond, O, amino, etc.; G1 = (un)substituted cyclic ring; and pharmaceutically acceptable salts or solvates thereof] were prepared as metalloproteinase (MMP) inhibitors. For example, II was provided in a multi-step synthesis starting from the reaction of 5-(chloromethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one with benzyl mercaptan. I were tested for inhibition of human MMP12, MMP9, MMP2, MMP19, MMP14 and MMP8. I and their pharmaceutical compns. are useful as MMP inhibitors for the treatment of asthma or other MMP-12 and/or MMP-9 mediated diseases (no data).
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2000:842129 CAPLUS Full-text
DOCUMENT NUMBER: 134:29418
TITLE: Preparation of New triazoles as pharmaceutically active compounds activity as kinase inhibitors

INVENTOR(S): Karabelas, Kostas; Lepisto, Matti; Sjo, Peter
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071537	A1	20001130	WO 2000-SE1009	20000519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2372743	A1	20001130	CA 2000-2372743	20000519
BR 2000010520	A	20020219	BR 2000-10520	20000519
EP 1183252	A1	20020306	EP 2000-931873	20000519
EP 1183252	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003500404	T	20030107	JP 2000-619794	20000519
NZ 515281	A	20030829	NZ 2000-515281	20000519
AT 259798	T	20040315	AT 2000-931873	20000519
US 6492406	B1	20021210	US 2000-646972	20000925
ZA 2001009049	A	20030203	ZA 2001-9049	20011101
NO 2001005664	A	20020121	NO 2001-5664	20011120
MX 2001PA11884	A	20020506	MX 2001-PA11884	20011121

PRIORITY APPLN. INFO.:
SE 1999-1854 A 19990521
SE 2000-645 A 20000228
WO 2000-SE1009 W 20000519

OTHER SOURCE(S): MARPAT 134:29418
GI



I



I

AB Title compds. [I; wherein one of Ar and Ar is optionally substitute d bicyclic heteroaryl or optionally substituted tricyclic heteroaryl and the other is optionally substituted heteroaryl or optionally substituted aryl; X is O or S; and R is H, OH, NH or C alkyl (itself optionally substituted by amino or hydroxy)], stereoisomers, salts, and solvates which are protein kinase C inhibitors are prepared and pharmaceutical compns. comprising them are useful to include prophylactic, diagnostic and therapeutic regimens carried out in vivo or ex vivo on humans or other mammals. Thus, the title compound II was prepared

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:771134 CAPLUS Full-text
DOCUMENT NUMBER: 149:104697
TITLE: Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders and their preparation
INVENTOR(S): Berger, Markus; Dahmen, Jan; Eriksson, Anders; Gabos, Balint; Hansson, Thomas; Hemmerling, Martin; Henriksson, Krister; Ivanova, Svetlana; Lepistoe, Matti; McKerrecher, Darren; Munck Af Rosenschoeld, Magnus; Nilsson, Stinabritt; Rehwinkel, Hartmut; Taflin, Camilla
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Bayer Schering Pharma Aktiengesellschaft
SOURCE: PCT Int. Appl., 310pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076048	A1	20080626	WO 2007-SE1136	20071220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,				

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

US 20080214641 A1 20080904 US 2007-5066 20071220
PRIORITY APPLN. INFO.: US 2006-871184P P 20061221
US 2007-941745P P 20070604
US 2007-978526P P 20071009

OTHER SOURCE(S): MARPAT 149:104697

GI



I



II

AB The present invention relates to indazolyl ester or amide derivs. of formula I, to pharmaceutical compns. comprising such derivs., to processes for preparing such novel derivs. and to the use of such derivs. as medicaments. Compds. of formula I wherein A is C1-6 (hydroxy)alkyl, C1-6 cyanoalkyl, CN, C1-6 nitroalkyl, NO2, C1-6 alkoxy, etc.; Rx is H; RxA taken together to form azacyclic ring; R1 and R1a is H, C1-4 (hydroxy)alkyl, C1-4 alkyl-O-C1-4 alkyl, C1-4 alkyl-S-C1-4 alkyl, C1-4 haloalkyl; R1R1a taken together to form oxo; R2 is H and C1-4 alkyl; R3 is (un)substituted C5-10 aryl(oxy), (un)substituted C5-10 aryl-C1-4 alkyl, (un)substituted C5-10 aryloxy-C1-4 alkyl and (un)substituted C5-10 heteroaryl; R4 is H, OH, halo, and C1-4 (halo)alkyl; W is H, (un)substituted Ph, (un)substituted C1-4 alkyl, (un)substituted C3-7 cycloalkyl, (un)substituted thienyl, (un)substituted isoxazolyl, (un)substituted pyrazolyl, (un)substituted pyridinyl, (un)substituted pyridazinyl, and (un)substituted pyrimidinyl; X is CH2, O, S, SO, SO2, NH and N-C1-4 alkyl; Y is H, halo, C1-4 (halo)alkyl, C1-4 alkoxy, C1-4 thioalkyl, etc.; Z is O and S; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their GR inhibitory

activity. From the assay, it was determined that compound II exhibited IC50 value of 2.3 nM.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1148723 CAPLUS Full-text
DOCUMENT NUMBER: 147:477019
TITLE: Multi-functionalized platinum(II) acetylides for optical power limiting
AUTHOR(S): Westlund, Robert; Malmstroem, Eva; Hoffmann, Markus; Vestberg, Robert; Hawker, Craig; Glimsdal, Eirik; Lindgren, Mikael; Norman, Patrick; Eriksson, Anders; Lopes, Cesar
CORPORATE SOURCE: KTH Fibre and Polymer Technology, Royal Institute of Technology, Stockholm, SE-100 44, Swed.
SOURCE: Proceedings of SPIE-The International Society for Optical Engineering (2006), 6401(Optical Materials in Defence Systems Technology III), 64010H/1-64010H/8 CODEN: PSISDG; ISSN: 0277-786X
PUBLISHER: SPIE-The International Society for Optical Engineering
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Preliminary results on the optical power limiting properties of Pt(II) acetylides containing triazole units are presented. The triazole units give a pos. contribution to the limiting abilities of the Pt(II) acetylide and this modified chromophore could have potential use in sensor protection devices. The versatile building block 2,2-bis(methylol)propionic acid (bis-MPA) can be used advantageously to functionalize nonlinear optical (NLO) Pt(II) acetylides. The bis-MPA units can be used to prepare dendritic substituents offering site isolation to the chromophore leading to improved clamping. The bis-MPA functionalization also improves the solubility of the Pt(II) acetylides in many organic solvents. The preparation of solid-state optical power limiters, where the NLO chromophore is inserted in an optically transparent matrix, is addressed. Again, the bis-MPA unit can be employed to increase the number of accessible end-groups to which matrix-compatible species can be attached. The hydroxy-functional Pt(II) acetylides can be modified to fit almost any matrix, organic or inorg. Finally, depending on functionalization, it is possible to prepare doped glasses where the chromophore is either embedded in the matrix, or covalently bonded to the matrix.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 5 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2003-018783 [01] WPIX
CROSS REFERENCE: 2002-732863; 2002-750527; 2002-750528; 2002-759874; 2002-759875
DOC. NO. CPI: C2003-004563 [01]
TITLE: New compounds useful as metalloproteinase inhibitors for the treatment of conditions such as asthma
DERWENT CLASS: B03
INVENTOR: LEPISTO M; LEPISTOE M; MUNCH AF ROSENSCHOELD M; MUNCK AF ROSENSCHOELD M; MUNCK AF ROSENSCHOLD M; MUNCK A R M
PATENT ASSIGNEE: (ASTR-C) ASTRAZENECA AB; (LEPI-I) LEPISTO M; (ROSE-I) MUNCK AF ROSENSCHOLD M
COUNTRY COUNT: 99

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2002074752	A1	20020926	(200301)*	EN	110[0]	
NO 2003004027	A	20031105	(200380)	NO		
EP 1370538	A1	20031217	(200402)	EN		
BR 2002008062	A	20040302	(200419)	PT		
CZ 2003002498	A3	20040317	(200430)	CS		
AU 2002237633	A1	20021003	(200432)	EN		
SK 2003001091	A3	20040504	(200433)	SK		
US 20040110809	A1	20040610	(200438)	EN		
JP 2004527512	W	20040909	(200459)	JA	188	
HU 2004000328	A2	20040928	(200470)	HU		
MX 2003008187	A1	20040201	(200473)	ES		
ZA 2003006738	A	20050223	(200519)	EN	117	
NZ 528141	A	20050527	(200537)	EN		
RU 2293730	C2	20070220	(200752)	RU		
AU 2002237633	B2	20070405	(200763)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002074752	A1	WO 2002-SE479	20020313
MX 2003008187	A1	WO 2002-SE479	20010313
AU 2002237633	A1	AU 2002-237633	20020313
BR 2002008062	A	BR 2002-8062	20020313
EP 1370538	A1	EP 2002-704038	20020313
JP 2004527512	W	JP 2002-573761	20020313
NZ 528141	A	NZ 2002-528141	20020313
NO 2003004027	A	WO 2002-SE479	20020313
EP 1370538	A1	WO 2002-SE479	20020313
BR 2002008062	A	WO 2002-SE479	20020313
CZ 2003002498	A3	WO 2002-SE479	20020313
SK 2003001091	A3	WO 2002-SE479	20020313
US 20040110809	A1	WO 2002-SE479	20020313
JP 2004527512	W	WO 2002-SE479	20020313
HU 2004000328	A2	WO 2002-SE479	20020313
NZ 528141	A	WO 2002-SE479	20020313
RU 2293730	C2	WO 2002-SE479	20020313
CZ 2003002498	A3	CZ 2003-2498	20020313
RU 2293730	C2	RU 2003-127736	20020313
SK 2003001091	A3	SK 2003-1091	20020313
ZA 2003006738	A	ZA 2003-6738	20030828
MX 2003008187	A1	MX 2003-8187	20030910
NO 2003004027	A	NO 2003-4027	20030911
HU 2004000328	A2	HU 2004-328	20020313
US 20040110809	A1	US 2004-471499	20040112
AU 2002237633	B2	AU 2002-237633	20020313

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 1370538	A1	Based on	WO 2002074752	A
BR 2002008062	A	Based on	WO 2002074752	A
CZ 2003002498	A3	Based on	WO 2002074752	A
AU 2002237633	A1	Based on	WO 2002074752	A
SK 2003001091	A3	Based on	WO 2002074752	A
JP 2004527512	W	Based on	WO 2002074752	A
HU 2004000328	A2	Based on	WO 2002074752	A

```
      MX 2003008187   A1     Based on         WO 2002074752   A
      NZ 528141       A      Based on         WO 2002074752   A
      RU 2293730      C2     Based on         WO 2002074752   A
      AU 2002237633   B2     Based on         WO 2002074752   A

PRIORITY APPLN. INFO: SE 2001-903          20010315
AN   2003-018783 [01]   WPIX
CR   2002-732863; 2002-750527; 2002-750528; 2002-759874; 2002-759875
AB   WO 2002074752 A1   UPAB: 20060118
      NOVELTY - Substituted imidazolidine, oxazolidine or thiazolidine are new.
            DETAILED DESCRIPTION - Compounds of formula (I) or their salts and in
      vivo hydrolysable esters are new.
            X = NR1, O or S;
            Y1 and Y2 = O or S;
            Z = NR2, O or S;
            m = 0 or 1;
            A = e.g. a direct bond, alkyl or alkenyl;
            R1 and R2 = H or (halo)alkyl;
            R4 = e.g. H, alkyl;
            R5 = a bicyclic or tricyclic group comprising 2 or 3 ring structures
      each of 3 - 7 ring atoms;
            R3 and R6 = e.g. H, halo, alkyl, aryl.
            Full definitions are given in the Definitions Field (Full Definitions).
            An INDEPENDENT CLAIM is included for use of a compound of formula (I)
      or its in vivo hydrolysable precursor in the preparation of a medicament for
      the treatment of a disease or condition mediated by at least one
      metalloproteinase enzyme.
            ACTIVITY - Antiasthmatic; Antiallergic; Antiinflammatory;
      Antirheumatic; Antiarthritic; Osteopathic; Antiarteriosclerotic; Vasotropic;
      Cytostatic; Cardiant; Gynecological; CNS-Gen.; Nootropic; Neuroprotective.
            MECHANISM OF ACTION - Metalloproteinase (MMP) (preferably MMP12, MMP13,
      MMP9 and/or MMP8) inhibitor; Tumor necrosis factor inhibitor.
            Test details are described, but no specific results for specific
      compounds are given.
            USE - Compound (I) is used for the treatment of a disease or condition
      mediated by a metalloproteinase in a warm blooded animal (claimed), such as
      asthma, rhinitis, chronic obstructive pulmonary disease (COPD), arthritis
      (such as rheumatoid arthritis and osteoarthritis), atherosclerosis and
      restenosis, cancer, invasion and metastasis, diseases involving tissue
      destruction, loosening of hip joint replacements, periodontal disease,
      fibrotic disease, infarction and heart disease, liver and renal fibroids,
      endometriosis, diseases related to the weakening of the extracellular matrix,
      heart failure, aortic aneurysms, CNS related diseases (such as Alzheimer's
      disease and multiple sclerosis (MS)) and hematological disorders.
            ADVANTAGE - The compounds exhibit improved potency, selectivity and/or
      pharmacokinetic properties. The compounds show an in vitro IC50 value of (0.1
      - 10000, preferably 0.1 - 1000) nM.



=> d his nofil

     (FILE 'HOME' ENTERED AT 10:45:11 ON 12 JAN 2009)

     FILE 'REGISTRY' ENTERED AT 10:45:16 ON 12 JAN 2009
L1              STR
L2              STR L1
L3            0 SEA SSS SAM L2
L4            1 SEA SSS FUL L2
```

```
                D SCA

     FILE 'CAPLUS' ENTERED AT 10:49:47 ON 12 JAN 2009
                E US2006-593543/APPS
L5             2 SEA SPE=ON  ABB=ON  PLU=ON  US2006-593543/AP
                D SCA TI
L6             1 SEA SPE=ON  ABB=ON  PLU=ON  L5 AND TRIAZ?
                SEL RN

     FILE 'REGISTRY' ENTERED AT 10:51:17 ON 12 JAN 2009
L7            53 SEA SPE=ON  ABB=ON  PLU=ON  (100-53-8/BI OR 100991-09-1/BI OR
                   1037628-17-3/BI OR 14001-66-2/BI OR 146480-36-6/BI OR 14874-70-
                   5/BI OR 16110-09-1/BI OR 177984-27-9/BI OR 177984-28-0/BI OR
                   252742-72-6/BI OR 260441-44-9/BI OR 26905-02-2/BI OR 2899-66-3/
                   BI OR 38212-33-8/BI OR 477904-80-6/BI OR 5382-16-1/BI OR
                   55444-67-2/BI OR 563-41-7/BI OR 64-04-0/BI OR 73901-41-4/BI OR
                   79099-07-3/BI OR 866602-59-7/BI OR 866602-60-0/BI OR 866602-61-
                   1/BI OR 866602-62-2/BI OR 866602-63-3/BI OR 866602-64-4/BI OR
                   866602-65-5/BI OR 866602-66-6/BI OR 866602-67-7/BI OR 866602-68
                   -8/BI OR 866602-69-9/BI OR 866602-70-2/BI OR 866602-71-3/BI OR
                   866602-72-4/BI OR 866602-73-5/BI OR 866602-74-6/BI OR 866602-75
                   -7/BI OR 866602-76-8/BI OR 866602-77-9/BI OR 866602-78-0/BI OR
                   866602-79-1/BI OR 866602-80-4/BI OR 866602-81-5/BI OR 866602-82
                   -6/BI OR 866602-83-7/BI OR 866602-84-8/BI OR 866602-85-9/BI OR
                   866602-86-0/BI OR 866602-88-2/BI OR 866602-89-3/BI OR 866602-90
                   -6/BI OR 9004-06-2/BI)
L8            23 SEA SPE=ON  ABB=ON  PLU=ON  L7 AND N2CNC/ESS
L9                STR L2
L10            1 SEA SSS SAM L9
L11           35 SEA SSS FUL L9

     FILE 'CAPLUS' ENTERED AT 11:00:54 ON 12 JAN 2009
L12           10 SEA SPE=ON  ABB=ON  PLU=ON  L11

     FILE 'REGISTRY' ENTERED AT 11:01:11 ON 12 JAN 2009
L13               STR L9
L14            5 SEA SUB=L11 SSS FUL L13
L15               STR L13
L16            0 SEA SSS SAM L15
L17            0 SEA SUB=L11 SSS FUL L15
L18           15 SEA SPE=ON  ABB=ON  PLU=ON  L11 AND L7

     FILE 'CAPLUS, DISSABS, CONFSCI, WPIX' ENTERED AT 11:04:29 ON 12 JAN 2009
L19          496 SEA SPE=ON  ABB=ON  PLU=ON  ERIKSSON A/AU OR ERIKSSON ANDER?/AU

L20           38 SEA SPE=ON  ABB=ON  PLU=ON  LEPISTO M/AU OR LEPISTO M ?/AU OR
                   LEPISTO MATT?/AU
L21          613 SEA SPE=ON  ABB=ON  PLU=ON  L19 OR ERIKSSON A ?/AU
L22          643 SEA SPE=ON  ABB=ON  PLU=ON  (L20 OR L21)
L23            7 SEA SPE=ON  ABB=ON  PLU=ON  L22 AND TRIAZOL?

     FILE 'CAPLUS' ENTERED AT 11:05:54 ON 12 JAN 2009
                D QUE L12
                D L12 IBIB ABS HITSTR TOT

     FILE 'CAPLUS, DISSABS, CONFSCI, WPIX' ENTERED AT 11:06:19 ON 12 JAN 2009
                D QUE L23
L24            5 DUP REM L23 (2 DUPLICATES REMOVED)
                       ANSWERS '1-4' FROM FILE CAPLUS
                       ANSWER '5' FROM FILE WPIX
```

```
D L24 IBIB ABS TOT
```